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Statins and hypothyroidism, independently, can rarely cause rhabdomyolysis. The combination of them especially with concurrent
intake of drugs such as diltiazem increases the risk of rhabdomyolysis. Hashimoto’s encephalopathy is a rare condition associated
with Hashimoto’s thyroiditis and some patients with that can present with a stroke like picture. An elderly male who has been
on atorvastatin for three years and on diltiazem for a week presented with sudden onset inability to walk and confusion. On
examinationmuscle tendernesswas noticed and creatine kinase levels indicated rhabdomyolysiswhichwe attributed to atorvastatin.
Patient developed a seizure and myoclonus of masseters. Considering this, his confusion and his neutrophilia and high C-reactive
protein levels, empirical antibiotics with dexamethasone were started and the patient responded to that. His cerebrospinal fluid and
blood culture reports that arrived later did not show sepsis. After going home also his CK (creatine kinase) levels remained high;
TSH (thyroid-stimulating hormone) level test was done and hypothyroidism was diagnosed. His antithyroid peroxidase antibody
levels were also very high. We retrospectively think he had Hashimoto’s encephalopathy as well. His lipid profile and TSH and CK
values returned to normal in that order after a few months of levothyroxine therapy.
1. Introduction
Hashimoto’s thyroiditis, the commonest form of hypothy-
roidism, affects 2–4% of the population [1] and up to 60
percent of people with thyroid diseases are unaware of
their disease even in some developed countries [2]. Undiag-
nosed hypothyroidism per se can cause rhabdomyolysis [3].
According to the World Health Organization in 2008 the
global prevalence of raised total cholesterol among adults
(≥5.0mmol/l) was 39% [4] and statins are the mainstay drugs
used to control hypercholesterolemia.Undiagnosed hypothy-
roidism can present as hypercholesterolemia. Cytochrome
P450 (CYP) 3A4 is the most abundant enzyme of CYPs in
the liver and intestines that metabolize approximately 50%
of currently available drugs including statins [5]. CYP 3A4
inhibitors including calcium channel blockers like diltiazem
are also widely prescribed and they increase plasma levels
of statins [6, 7]. Therefore simultaneous intake of calcium
channel blockers with statins increases the risk of developing
rhabdomyolysis [6]. This risk is further increased by concur-
rent undiagnosed hypothyroidism [6]. Many doctors known
to us prescribe the combination of statins and diltiazem com-
monly. During the 1996–2012 period, atorvastatin became
the best-selling drug in the human history [8]. Despite the
aforesaid background, lack of case reports of atorvastatin-
diltiazem and undiagnosed hypothyroidism combination
induced rhabdomyolysis indicates this important problem is
underdetected and underreported. However, our literature
survey found one case report of rhabdomyolysis due to ator-
vastatin-diltiazem combination [9].
Hashimoto’s encephalopathy (HE), also known in other
names, is a rare syndrome associated with Hashimoto thy-
roiditis with high antithyroid peroxidase (TPO) antibody lev-
els [10, 11]. It is often characterized by acute or subacute onset
of confusion with altered level of consciousness, seizures, and
myoclonus [10, 11]. It can present as a stroke like pattern or
slowly progressive cognitive impairment, but these patterns
can overlap [10]. HE responds well to steroids [10, 11].
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Table 1: The summery of the laboratory workup results of this patient.
Investigation Referencerange Value/the day at hospital on which the test was done is within brackets
Creatine kinase (CK) in U/l 38–174 3169.5 (1)→2382.4 (3)→1233.0 (5)
White cell count (×109/l) 4.0–10.0 10.7 (1)→11.84 (4)
Neutrophils % 50–70 76.7% (1)→88.6 (4)
Lymphocytes% 20–40 17.3% (1)→8.4 (4)
Hemoglobin (g/dL) 11–16 14.1 (1)→11.2 (4)
Hematocrit (%) 37–54 42% (1)→32 (4)
Platelets count (×109/l) 150–450 145
Reticulocyte count 0.5–1.5% 2.6% (4)
Serum alanine transaminase (ALT) in U/l 7.0–28 77 (1)
Serum aspartate transaminase (AST) in U/l 13.0–31.0 229 (1)→210 (3)
Serum alkaline phosphatase (ALP) in U/l 207.2→210
Serum C-reactive protein (CRP) in mg/l 5.2 (1)→144.2 (4)→28 (9)
Blood urea (mmol/l) 2.1–7.1 6.0 (1)→6.8 (2)→8.4 (3)→7.0 (6)
Serum creatinine (mg/dL) 0.9–1.30 1.25 (1)→1.0 (2)→1.25 (3)→1.28 (4)→1.20 (6)→0.89 (8)
Serum sodium (mmol/l) 133–148 110 (1)→126 (1)→130 (2)→116 (3)→116 (4)→130 (5)→127 (6)→130 (7)→137 (8)
Serum potassium (mmol/l) 3.5–5.3 2.6 (1)→4.0 (1)→5.0 (2)→2.6 (3)→2.3 (4)→2.1 (5)→3.9 (6)→3.1 (7)→3.5 (8)
Serum calcium (mmol/l) 2.10–2.55 2.07 (1)→2.04 (2)→2.35 (5)
Urine full report Pus cells 5 per HPF, Red Cells 8–10 per HPF and Albumin + (2)
ESR (mm/hour) <20 7 (2)
Fasting blood sugar (mg/dL) 70–126 108 (2)
Blood culture No growth (4)
Urine culture No growth (4)
2. Case Report
A 72-year-old average-built male presented with the first
attack of sudden onset weakness of both legs and inability to
walk, impairedmemory and confusion, and abnormal behav-
ior for three days. He has been on treatment for hypertension
and dyslipidemia during the previous three years. At the
time of admission hewas on losartan, aspirin, hydrochloroth-
iazide, diltiazem, and atorvastatin. There was no history of
fever, any trauma or strenuous exertion in the recent past,
diabetes, thyroid diseases, backache, seizures, slurring of
speech, numbness, or loss of sensations of limbs. He was
used to consuming alcohol approximately once a month. On
examination his pulse rate was 70/minute; blood pressure
was 130/80mmHg; cardiovascular, respiratory, abdominal,
and nervous system examinations were unremarkable except
muscle power was 4/5 and all tendon reflexes were dimin-
ished in all four limbs. Tenderness of muscles was noticed
on examination which aggravated towards the third day at
hospital and then gradually improved and subsided by the
eighth day.However, he complained ofmuscle pain only from
day 2 at hospital. Table 1 shows his laboratory investigation
results.
His noncontrast computed tomography of brain was nor-
mal. Initial laboratory investigation results showed hypona-
tremia and hypokalemia; hence hydrochlorothiazide was
omitted. We initially assumed hyponatremia as the cause of
his confusion and corrected that with normal saline infu-
sions.
His initial CK level was >18 times higher than the
normal upper limit. Atorvastatin induced rhabdomyolysis
was diagnosed and that drug was stopped. Intravenous
normal saline 2-3 l per day was infused and adequate urine
output was maintained. His hypokalemia was corrected with
intravenous KCl infusions. On the third day he developed
one attack of convulsions lasting for <5 minutes. On day
4 we started empirical intravenous ceftriaxone and dexam-
ethasone considering his persisting confusion, neutrophilia
and high CRP levels, and previous day convulsions. However,
there were no fever and signs like neck stiffness. Those
two drugs were continued for seven days while waiting for
reports of CSF obtained by lumbar puncture, blood, and
urine culture reports. Those reports did not show evidence
of any infection. However CSF protein level was 70mg/dL.
Patient had an episode of myoclonus of masseter muscles and
generalized increase of muscle tone on the same day (day 4)
that subsided on the following day; nerve conduction velocity
studies showed predominantly sensory axonal polyneuropa-
thy and marginally low motor conduction velocity. Electro
encephalogram (EEG) showed low amplitude cortical activ-
ity in slower range. Patient’s muscle tenderness gradually
reduced; he was able to walk and became rational and well
oriented and on day 8 he was sent home and asked to come
to our clinic in a week for a review.
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After a week the patient was rational and well oriented
and could walk. The CK level was 213U/l, but it again
increased and has not decreased below 386U/l when the
test was repeated later in spite of not being on atorvastatin.
He was reassessed; considering CK levels, his hyponatremia
and hypokalemia, and slow relaxing ankle jerk, hypothy-
roidism was suspected. When asked him to think carefully
and answer; he admitted that he felt lethargic and there
were episodes of impaired memory on and off for about
10 months before his acute illness. He had mentioned his
memory impairment to his general practitioner (GP) during
his last visit. But there was no voice change, constipation,
weight gain, changes of skin or libido, hair loss in the recent
past, cold intolerance, or joint pains. And he insisted his
inability to walk and confusion were of sudden onset and
his wife vouched for him. He had very high TSH levels
(86.1mIU/l, normal range 0.3–4.2mIU/l). Hypothyroidism
was diagnosed. Levothyroxine 25 micrograms (𝜇g) per day
was started and gradually increased up to 75𝜇g per day. His
(TPO) antibody level was >1000 IU/mL (normal< 35 IU/mL)
and that test was repeated and confirmed. Further literature
survey by first author enlightened us of risk of atorvastatin-
diltiazem combination and the likelihood of him having
Hashimoto’s encephalopathy also while he was hospitalized.
His TSH levels reduced progressively but not the CK
levels. After levothyroxine intake was increased above 100 𝜇g
per day, CK levels also started to decrease to normal level
gradually.
His lipid profile done two months after starting levothy-
roxine was normal. After 10 months his TSH, CK, and lipid
profiles were normal; hewas healthy except for a discoid ecze-
matous rash developed in limbs that responded to topical
steroids.
3. Discussion
This patient presented to us with history more suggestive of a
neurological problem. He did not complain of myalgia on or
before admission.Detection ofmuscle tenderness on physical
examination and then a very high CK levels directed us to
diagnose statin induced rhabdomyolysis. He had confusion,
hyponatremia, and myalgia but denied history of any thyroid
problems; other common symptoms of hypothyroidism were
not there and there was no goiter. We relied on that and
did not order TSH test earlier. Persistence of his high CK
levels long after stopping atorvastatin compelled us to rethink
which led us towards the diagnosis of underlying hypothy-
roidism. In younger patients with dyslipidemia we and most
doctors known to us try to exclude hypothyroidism but this
case shows there may be a place for doing that even in the
case of older patients if there is some suspicion. However, in
countries with limited resources like ours we have to limit the
laboratory investigations. It is well known that hypothyroi-
dism has diverse and unusual and uncommon presentations.
This is a very unusual presentation.
This patient has been on treatment from a GP for hyper-
tension and dyslipidemia. He has been on atorvastatin for
three years. However he did not visit his GP regularly. For
example, during the year preceding admission to the hospital,
for 10 consecutive months he purchased the same drugs
from a pharmacy showing the same old prescription. It is a
common practice in Sri Lanka to avoid doctors’ fees in the
private sector or to avoid long waiting and congestion of state
hospitals like ours that provide free service including drugs.
That may have contributed to nondetection of his hypothy-
roidism earlier. Then he changed his GP who replaced
metoprolol of his drug list with diltiazem. We presume that
patient’s complaining of memory impairment to his new GP
led to replacement of metoprolol. One week after that, the
combination of undiagnosed hypothyroidism, atorvastatin,
and diltiazem would have caused his rhabdomyolysis.
There is one case report from China about rhabdomyol-
ysis induced by simvastatin-diltiazem interaction in unrec-
ognized hypothyroidism [6]. In contrast to our patient he
has been on simvastatin for about a year; one month before
presentation diltiazem was started and he presented with
myalgia for 25 days [6]. Considering that both statins and
calcium channel blockers are prescribed very commonly,
undiagnosed hypothyroidism is also common and rhab-
domyolysis is life-threatening; this case would be a valuable
reminder to clinicians.
This patient’s very high anti-TPO antibody levels indi-
cate that he has Hashimoto’s disease. His sudden onset of
presenting symptoms (that mimic a cerebrovascular event
with confusion) of seizure and myoclonus at the hospital
and normal CSF report except high protein level all point
towards Hashimoto’s encephalopathy [10, 11]. We suspected
those symptoms were of possible meningoencephalitis and
gave him intravenous dexamethasone adjuvant to ceftriaxone
to prevent further neurological sequelae and that may have
resulted in him recovering fromHashimoto’s encephalopathy
[10]. As he well responded to that treatment and even CSF
and blood culture reports did not show evidence of any
sepsis, we continued that treatment. Looking retrospectively
we think it is likely that had a concurrent attack of HE (not
meningoencephalitis) that well responded to dexamethasone.
Hyponatremia and hypokalemia which we initially suspected
as reasons for his symptoms can be associated with HE [12].
Nonetheless HE usually need longer course of steroids to
recover and our patient did not get recurrences during the
following 14 months as about half of HE patients do [11].
This may be the first reported case of undiagnosed
hypothyroid patient presenting with concurrent proba-
ble Hashimoto’s encephalopathy and atorvastatin-diltiazem
combination induced rhabdomyolysis.This case reiterates the
importance of knowledge of drug interactions in day to day
practice and the need to be cautious of potential myopathy
when prescribing statins to hypothyroid patients, especially
in combination with cytochrome P450 3A4 inhibitors. This
case exemplifies the risks of buying drugs from pharmacies
repeatedly using old prescriptions without being seen by a
doctor. This illustrates importance of looking for possible
drug interactions and hypothyroidism in the cases of statin
induced myositis/rhabdomyolysis as well. For grey cases of
meningitis with seizures we start antibiotics with dexametha-
sone pending CSF reports. If the patient improves even if
the report comes negative, we presume our clinical diagnosis
as correct. This case demonstrates we have to consider rare
possibilities like HE also in such instances.
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